@BillBrrr@WebullGlobal Yes! I use the ladder on desktop and it’s been lagging for long periods of time. If I try and drag a stop to move it up it will freeze. It won’t move to the new price and it won’t let you cancel the order because it’s “being modified.” It has been horrible the past few days!
@andymewborn That’s great and all, but you didn’t mention that Live Nation has a $75mm stake in the company. They pump these things across their concert venues for $10 a can. And it’s the only option for water. Yes, some of this can be attributed to marketing. But most of it is forced sales.
@cs_tradess Thanks for the reply! I really do like your strategy and how it gives clear entries. I find myself seeing a lot of the trades you take before you post them, so that makes me feel like I’m catching on. I just need to be more confident in the execution.
@cs_tradess That's how I normally take plays. I feel better when all three EMAs are in line where they should be. I was just curious to what you saw on these entries at the 200. Thanks for the reply. I do like your strategy so far. It's working pretty well from what I have tested.
@cs_tradess 1/2 Did you take these trades off the 200 rejection? I have been playing with your strategy a bit lately and it seems you put a lot of weight on the reject of the 13. In the META and AAPL charts the 13 is above the 48, which to me is more bullish, even if still below the 200.
@Amarincorp@Amarincorp your stock price has plummeted, your sales are in the toilet, your BOD has been absent for years, and your PR's are non-existent. This is what you have been spending your time on? Holiday recipes? Are you kidding us right now? How about your only drug you sell?
$AMRN It really seems like the judges were in over their heads and used Rule 36 to get a head start on a holiday weekend.
https://t.co/c3BLXBZaYF...
Is it possible to bring suit against the PTAB? Nobody would have though they would go after the FDA, but they did. And they won.
@semodough It’s disgusting, isn’t it? Where is the incentive for bios to research groundbreaking therapies going forward if this is the stance the courts take?
EVAPORATE showed that icosapent ethyl 4 g/day reduces low attenuation plaque volume at 18 months compared with placebo among patients with known #cvCAD, as assessed by cardiac CTA. Read more: https://t.co/kfhL8F2jp1 #ESCCongress